Males with lupus nephritis had higher all-cause mortality and proportion of infection-related death compared to females.

REPEAT kidney biopsies may play an essential role in managing lupus nephritis, particularly for patients whose disease ...

Panelists discuss the challenges patients face in accessing lupus nephritis treatment and the resources available to support ...

Kezar (KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis so it can focus on ...

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.

On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...

Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response. Long-term follow-up data offer valuable ...

Exploring innovative therapies and market trends in lupus nephritis treatment, highlighting advancements in patient care and emerging drug developments.

The regulator's decision came after the company paused the study in September to review safety data following the deaths of ...

Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...